Research ArticleArticle
Open Access
COVID-19 Vaccine Uptake Among Patients With Systemic Lupus Erythematosus in the American Midwest: The Lupus Midwest Network (LUMEN)
Baptiste Chevet, Gabriel Figueroa-Parra, Jeffrey X. Yang, Cassondra A. Hulshizer, Tina M. Gunderson, Stephanie Q. Duong, Michael S. Putman, Kamil E. Barbour, Cynthia S. Crowson and Alí Duarte-García
The Journal of Rheumatology July 2022, jrheum.220220; DOI: https://doi.org/10.3899/jrheum.220220
Baptiste Chevet
The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH. B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali{at}mayo.edu. Accepted for publication June 17, 2022.
Gabriel Figueroa-Parra
The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH. B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali{at}mayo.edu. Accepted for publication June 17, 2022.
Jeffrey X. Yang
The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH. B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali{at}mayo.edu. Accepted for publication June 17, 2022.
Cassondra A. Hulshizer
The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH. B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali{at}mayo.edu. Accepted for publication June 17, 2022.
Tina M. Gunderson
The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH. B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali{at}mayo.edu. Accepted for publication June 17, 2022.
Stephanie Q. Duong
The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH. B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali{at}mayo.edu. Accepted for publication June 17, 2022.
Michael S. Putman
The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH. B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali{at}mayo.edu. Accepted for publication June 17, 2022.
Kamil E. Barbour
The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH. B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali{at}mayo.edu. Accepted for publication June 17, 2022.
Cynthia S. Crowson
The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH. B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali{at}mayo.edu. Accepted for publication June 17, 2022.
Alí Duarte-García
The Lupus Midwest Network (LUMEN) project is supported by the Centers for Disease Control and Prevention (CDC) of the US Department of Health and Human Services (HHS) under grant number U01 DP006491 as part of a financial assistance award totaling $1,750,000 with 100% funding by CDC/HHS. The Rochester Epidemiology Project was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01AG034676, and grant number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC/HHS, the US Government, or the NIH. B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France; G. Figueroa-Parra, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA; J.X. Yang, MD, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; C.A. Hulshizer, BA, T.M. Gunderson, MS, S.Q. Duong, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; M.S. Putman, MD, MSci, Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; C.S. Crowson, PhD, Division of Rheumatology, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA; A. Duarte-García, MD, MSc, Division of Rheumatology, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. B. Chevet and G. Figueroa-Parra contributed equally as co–primary authors. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. A. Duarte-García, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: duarte.ali{at}mayo.edu. Accepted for publication June 17, 2022.
Abstract
Objective Patients with systemic lupus erythematosus (SLE) are at higher risk of poor outcomes from coronavirus disease 2019 (COVID-19). The vaccination rate among such patients is unknown. We aimed to assess COVID-19 vaccine uptake among patients with SLE.
Methods We included 342 patients with SLE from the Lupus Midwest Network (LUMEN) and 350 age-, sex-, race-, and county-matched comparators. Vaccination uptake for influenza, pneumococcal, and zoster vaccines before pandemic restrictions began (up to February 29, 2020) was assessed. First-dose COVID-19 vaccine uptake was electronically retrieved and manually ascertained (December 15, 2020, to July 31, 2021). Time to COVID-19 vaccination, demographics, SLE manifestations, medications, Charlson Comorbidity Index, Area Deprivation Index, and Rural-Urban Commuting Area codes were compared.
Results On July 31, 2021, 83.3% of patients with SLE and 85.5% of comparators were vaccinated against COVID-19. The COVID-19 vaccination rates were similar among SLE and comparators (hazard ratio 0.93, 95% CI 0.79-1.10). Unvaccinated patients with SLE were more likely than vaccinated patients to be men (27.3% vs 14.1%), younger (mean age 54.1 vs 58.8 yrs), have a shorter SLE duration (median 7.3 vs 10.7 yrs), and be less frequently vaccinated with influenza and pneumococcal vaccines.
Conclusion Patients with SLE in the Lupus Midwest Network had similar COVID-19 vaccination uptake as matched comparators, most of whom were vaccinated early when the vaccine became available. One in 6 patients with SLE remain unvaccinated.
In this issue
The Journal of Rheumatology
Vol. 53, Issue 2
1 Feb 2026
COVID-19 Vaccine Uptake Among Patients With Systemic Lupus Erythematosus in the American Midwest: The Lupus Midwest Network (LUMEN)
Baptiste Chevet, Gabriel Figueroa-Parra, Jeffrey X. Yang, Cassondra A. Hulshizer, Tina M. Gunderson, Stephanie Q. Duong, Michael S. Putman, Kamil E. Barbour, Cynthia S. Crowson, Alí Duarte-García
The Journal of Rheumatology Jul 2022, jrheum.220220; DOI: 10.3899/jrheum.220220
COVID-19 Vaccine Uptake Among Patients With Systemic Lupus Erythematosus in the American Midwest: The Lupus Midwest Network (LUMEN)
Baptiste Chevet, Gabriel Figueroa-Parra, Jeffrey X. Yang, Cassondra A. Hulshizer, Tina M. Gunderson, Stephanie Q. Duong, Michael S. Putman, Kamil E. Barbour, Cynthia S. Crowson, Alí Duarte-García
The Journal of Rheumatology Jul 2022, jrheum.220220; DOI: 10.3899/jrheum.220220
